| Literature DB >> 28717181 |
Shisong Ma1,2, Michael Snyder3, Savithramma P Dinesh-Kumar4.
Abstract
Deciphering gene regulatory networks requires identification of gene expression modules. We describe a novel bottom-up approach to identify gene modules regulated by cis-regulatory motifs from a human gene co-expression network. Target genes of a cis-regulatory motif were identified from the network via the motif's enrichment or biased distribution towards transcription start sites in the promoters of co-expressed genes. A gene sub-network containing the target genes was extracted and used to derive gene modules. The analysis revealed known and novel gene modules regulated by the NF-Y motif. The binding of NF-Y proteins to these modules' gene promoters were verified using ENCODE ChIP-Seq data. The analyses also identified 8,048 Sp1 motif target genes, interestingly many of which were not detected by ENCODE ChIP-Seq. These target genes assemble into house-keeping, tissues-specific developmental, and immune response modules. Integration of Sp1 modules with genomic and epigenomic data indicates epigenetic control of Sp1 targets' expression in a cell/tissue specific manner. Finally, known and novel target genes and modules regulated by the YY1, RFX1, IRF1, and 34 other motifs were also identified. The study described here provides a valuable resource to understand transcriptional regulation of various human developmental, disease, or immunity pathways.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28717181 PMCID: PMC5514134 DOI: 10.1038/s41598-017-05705-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Characterization of the human co-expression network. (a) Histogram showing the distribution of the partial correlation coefficient (pcor) between gene pairs. Most gene pairs show pcors between -0.02 and 0.02. (b) A sub-network for immunity-related modules extracted from the entire gene co-expression network. In the network, each sphere represents a gene, and connection between genes indicates their similar expression pattern. Genes are colored according to their module identities. (c) A simplified version of the sub-network from B is shown. The genes from the same module are represented by a single sphere. The size of the sphere is proportional to the number of genes within a module. The number shown within the module sphere represents module # shown in Supplementary Dataset 1. The network is shown in a 3-D space layout and some modules (e.g. #477 and #851) are hidden behind modules in foreground.
Figure 2Motif target identified through motif position bias towards TSS. (a) A diagram showing a group of promoters. Within the promoters, a random/non-functional motif (grey triangle) distributes randomly along the promoters, while a functional motif (solid black triangle) distributes towards the transcription start site (TSS). The white bars represent transposon or repetitive sequence in the promoters, which are excluded from motif analysis. The arrow indicates the direction of transcription. (b) A representative distribution of a random/non-functional motif (grey line) and a functional motif (black line) with bias distribution along promoters. (c) Distribution of the NF-Y (CCAAT) motif within gene promoters from the modules regulated by this motif. Data from the first 10 modules shown in Supplementary Dataset 3 are indicated by different colors, as specified by the color key on the top left. (d) Distribution of the Sp1 motif within the gene promoters for modules regulated by the Sp1 motif. Data from first 10 modules shown in Supplementary Dataset 5 are indicated by different colors, as specified by the color key on the top left.
NF-Y motif (CCAAT)-regulated modules.
| Module No. | # of genes in the Module | GO Enrichment for the genes within the module | Binding of NF-YA/YB protein to the gene promoters within the module according to ENCODE data | ||||
|---|---|---|---|---|---|---|---|
| Enriched GO | GO Enrichment pValue | Selected Genes in the module with the enriched GO term | # of Genes in the module with NF-YA/B bound CCAAT motif in promoter | Binding Enrichment, Fold change, compared to genome-wide average level | Binding Enrichment pValue | ||
| 1 | 180 | cell cycle | 3.44E-76 | BRCA1/BRCA2/MSH2 | 113 | 2.23 | 2.1455E-22 |
| 2 | 109 | translational elongation | 6.24E-37 | RPSA/RPS19/RPL5 | 58 | 1.89 | 2.86376E-08 |
| 4 | 79 | response to endoplasmic reticulum stress | 2.86E-20 | HSPA5/XBP1/HSP90B1 | 63 | 2.83 | 1.79692E-21 |
| 7 | 66 | cholesterol biosynthetic process | 1.62E-35 | APOE/HMGCR/DHCR7 | 41 | 2.21 | 8.53E-09 |
| 8 | 64 | cellular amino acid metabolic process | 1.09E-10 | ATF4/CTH/WARS | 33 | 1.83 | 6.28382E-05 |
| 10 | 58 | nucleosome organization | 1.52E-31 | HIST2H2BE/HIST1H1C/HIST1H1B | 44 | 2.69 | 5.81052E-14 |
| 11 | 56 | pyruvate metabolic process | 8.06E-11 | GAPDH/ENO2/LDHA | 23 | 1.46 | 0.025308353 |
| 13 | 53 | RNA splicing | 7.55E-10 | PPP2CA/DDX5/SRSF2 | 30 | 2.01 | 1.26722E-05 |
| 15 | 51 | regulation of transcription, DNA-templated | 5.22E-10 | MBD2/MBD3/ZNF266 | 34 | 2.37 | 1.17185E-08 |
| 16 | 51 | RNA processing | 1.68E-10 | SSB/NOLC1/TGS1 | 22 | 1.53 | 0.015358532 |
| 18 | 45 | Golgi vesicle transport | 1.16E-09 | RP2/CREB3L2/USO1 | 21 | 1.66 | 0.006178619 |
| 19 | 44 | regulation of transcription, DNA-templated | 4.51E-21 | IRAK4/ZNF267/ZNF92 | 30 | 2.42 | 3.91083E-08 |
| 20 | 38 | organic acid catabolic process | 1.76E-14 | PPARA/GCDH/BCKDHB | 24 | 2.24 | 7.13037E-06 |
| 22 | 35 | protein polymerization | 7.88E-12 | TUBB3/TUBB/TUBA1A | 10 | 1.01 | 0.542074745 |
| 24 | 35 | circadian regulation of gene expression | 3.78E-08 | PER2/PER3/PER1 | 19 | 1.93 | 0.001000469 |
| 26 | 34 | protein folding | 7.22E-12 | HSPD1/HSPA8/HSPA9 | 14 | 1.46 | 0.070324677 |
| 29 | 30 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 7.47E-11 | HLA-DRB1/HLA-DPB1/HLA-DRA | 15 | 1.78 | 0.009139083 |
| 31 | 28 | regulation of developmental process | 1.54E-07 | TP53/CDKN1B/JUN | 16 | 2.03 | 0.001203638 |
| 36 | 25 | cilium organization | 3.45E-07 | ODF2/TMEM231 | 7 | 0.99 | 0.582218333 |
| 38 | 23 | cellular response to lipopolysaccharide | 9.79E-08 | IL1B/IL8/NFKBIA | 8 | 1.24 | 0.308349607 |
| 42 | 22 | cellular response to DNA damage stimulus | 2.14E-10 | CDKN1A/MDM2/BAX | 14 | 2.26 | 0.000551652 |
| 44 | 22 | regulation of transcription, DNA-templated | 2.57E-11 | ZNF350/ZNF667/ZNF569 | 8 | 1.29 | 0.261090348 |
| 45 | 22 | cellular respiration | 3.01E-08 | ATP5B/PDHA1/NDUFS2 | 12 | 1.94 | 0.008155563 |
| 48 | 21 | triglyceride metabolic process | 1.40E-11 | LIPE/DGAT2/GPD1 | 4 | 0.68 | 0.882989411 |
| 49 | 21 | fatty acid oxidation | 4.40E-08 | CPT2/PDK4/ACADVL | 11 | 1.86 | 0.016309781 |
| 53 | 18 | gland development | 1.29E-12 | SHH/BMP4/SNAI2 | 8 | 1.58 | 0.103963857 |
| 59 | 16 | platelet activation | 1.56E-09 | ILK/FLNA/ACTB | 8 | 1.78 | 0.052838504 |
| 62 | 15 | anterior/posterior pattern specification | 1.89E-12 | DKK1/HOXA10/HOXA1 | 3 | 0.71 | 0.838818923 |
| 63 | 14 | regulation of plasma lipoprotein particle levels | 3.62E-10 | ABCA1/ABCG1/MYLIP | 7 | 1.78 | 0.068971412 |
| 68 | 14 | embryonic limb morphogenesis | 1.06E-08 | HOXD13/FGF9/HOXA13 | 1 | 0.25 | 0.990266126 |
| 77 | 12 | mRNA processing | 1.38E-07 | HNRNPA1/HNRNPA2B1/PABPN1 | 3 | 0.89 | 0.700561294 |
| 83 | 10 | anterior/posterior pattern specification | 7.01E-09 | HOXC13/HOXC6/HOXC9 | 7 | 2.49 | 0.007218374 |
| 85 | 10 | regulation of cellular amino acid metabolic process | 2.10E-13 | PSMC5/PSMD2/PSMD1 | 2 | 0.71 | 0.819878552 |
Sp1 motif-regulated modules.
| Module No. | Catergory | Tissue | # of genes in the Module | GO or Pathway Enrichment for the genes within the module | Binding of Sp1 protein to the gene promoters within the module according to ENCODE data | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| GO | GO/Pathway Enrichment pValue | Selected genes in the module with the enriched GO term | Genes with SP1 bound SP1 motif in promoter | Binding Enrichment Fold change | Binding Enrichmentp Value | Binding Depletion pValue | ||||
| 5 | dev | blood vessel | 81 | angiogenesis | 9.91E-15 | NOS3/KDR/FLT1 | 9 | 0.27 | 1.49E-09 | |
| 7 | dev | skin | 73 | skin development | 9.33E-12 | TGM1/KLK7/KLK5 | 8 | 0.26 | 8.15E-09 | |
| 14 | dev | muscle | 69 | muscle system process | 2.26E-36 | NOS1/TNNI3/RYR1 | 14 | 0.49 | 1.42E-04 | |
| 17 | dev | nervous | 61 | synaptic transmission | 5.19E-14 | SLC6A3/TH/GRIN1 | 11 | 0.43 | 7.38E-05 | |
| 33 | dev | nervous | 47 | nervous system development | 4.33E-17 | KCNQ2/DCC/DLL1 | 7 | 0.36 | 7.50E-05 | |
| 42 | dev | reproduction | 40 | spermatogenesis | 2.11E-10 | DDX4/DDX25/SPO11 | 10 | 0.60 | 2.16E-02 | |
| 44 | dev | cartilage | 39 | connective tissue development | 3.59E-10 | COL2A1/COL11A2/COL10A1 | 9 | 0.55 | 1.21E-02 | |
| 46 | dev | liver | 38 | plasma lipoprotein particle assembly | 1.38E-12 | APOA1/APOB/APOA4 | 14 | 0.88 | 3.34E-01 | |
| 57 | dev | extracellular matrix | 33 | extracellular matrix organization | 5.86E-14 | MMP2/COL1A1/TNC | 10 | 0.73 | 1.25E-01 | |
| 60 | dev | extracellular matrix | 32 | extracellular matrix organization | 1.52E-09 | PDGFRA/COL1A2/DCN | 7 | 0.53 | 1.57E-02 | |
| 65 | dev | 31 | tissue morphogenesis | 4.02E-09 | HGF/IGFBP5/SFRP1 | 7 | 0.54 | 2.15E-02 | ||
| 66 | dev | skeletal | 31 | anterior/posterior pattern specification | 6.63E-16 | HOXA10/HOXA1/EN1 | 3 | 0.23 | 1.04E-04 | |
| 70 | dev | nervous | 29 | glial cell differentiation | 4.67E-09 | S100B/ERBB3/RELN | 1 | 0.08 | 3.47E-06 | |
| 78 | dev | liver | 28 | very-low-density lipoprotein particle clearance | 4.40E-08 | APOE/APOC3/APOC1 | 12 | 1.03 | 5.21E-01 | |
| 85 | dev | skin | 25 | skin development | 2.98E-10 | SFN/ITGA3/KRT5 | 6 | 0.58 | 5.29E-02 | |
| 91 | dev | stem cell | 24 | stem cell maintenance | 4.05E-07 | NANOG/NODAL/LIN28A | 10 | 1.00 | 5.77E-01 | |
| 96 | dev | 24 | regionalization | 1.66E-10 | FOXC1/SIX1/TBX3 | 4 | 0.40 | 8.79E-03 | ||
| 110 | dev | 22 | hemopoiesis | 4.16E-07 | SYK/HHEX/GATA2 | 8 | 0.87 | 3.92E-01 | ||
| 111 | dev | 22 | pattern specification process | 1.38E-10 | PAX6/PBX1/NR2F2 | 5 | 0.55 | 5.30E-02 | ||
| 152 | dev | pancreate | 16 | pancreatic A cell differentiation | 8.89E-12 | NEUROD1/INSM1/NKX2-2 | 1 | 0.15 | 2.23E-03 | |
| 212 | dev | thyroid | 12 | cellular modified amino acid metabolic process | 7.22E-08 | DUOX2/AHCY/DUOX1 | 2 | 0.40 | 6.71E-02 | |
| 217 | dev | nervous | 12 | negative regulation of glial cell differentiation | 1.24E-09 | FGFR3/ID2/ID4 | 4 | 0.80 | 3.92E-01 | |
| 255 | dev | reproduction | 10 | cilium assembly | 2.02E-09 | KIF3A/IFT88/FAM161A | 6 | 1.44 | 1.95E-01 | |
| 272 | dev | kidney | 9 | metanephros morphogenesis | 2.47E-07 | SMO/LGR4/FRAS1 | 3 | 0.80 | 4.41E-01 | |
| 2 | house | 134 | cell cycle | 2.85E-69 | BRCA1/BRCA2/BIRC5 | 94 | 1.68 | 1.85E-11 | ||
| 4 | house | 100 | cellular macromolecule metabolic process | 3.44E-07 | APC/ADD1/CSNK2A1 | 57 | 1.37 | 1.35E-03 | ||
| 6 | house | 79 | RNA metabolic process | 5.65E-10 | SP1/MTDH/PDPK1 | 47 | 1.43 | 1.01E-03 | ||
| 9 | house | 72 | pyruvate metabolic process | 1.38E-12 | ENO2/ENO1/DDIT4 | 33 | 1.10 | 2.72E-01 | ||
| 15 | house | 66 | regulation of macromolecule metabolic process | 3.18E-13 | MYC/JUN/EGR1 | 34 | 1.24 | 6.70E-02 | ||
| 16 | house | 65 | response to endoplasmic reticulum stress | 3.73E-20 | HSPA5/HSP90B1/PDIA3 | 51 | 1.88 | 1.43E-09 | 4.41E-01 | |
| 23 | house | 56 | protein folding | 1.30E-22 | HSP90AA1/HSPD1/HSPA8 | 36 | 1.54 | 5.14E-04 | ||
| 26 | house | 55 | translational elongation | 2.74E-38 | RPS19/RPL11/RPL5 | 41 | 1.79 | 7.19E-07 | ||
| 31 | house | 48 | RNA processing | 2.44E-10 | EIF4E/SRSF1/HNRNPD | 32 | 1.60 | 4.00E-04 | ||
| 32 | house | 47 | lipid biosynthetic process | 4.96E-26 | SREBF1/FASN/PNPLA3 | 40 | 2.04 | 9.29E-10 | ||
| 34 | house | 47 | mRNA metabolic process | 6.22E-09 | PRMT5/PSMA6/RPS17 | 28 | 1.43 | 9.87E-03 | ||
| 36 | house | 45 | cellular response to DNA damage stimulus | 4.84E-14 | CDKN1A/MDM2/PCNA | 28 | 1.49 | 4.24E-03 | ||
| 37 | house | 44 | histone modification | 1.79E-13 | MLL/EP300/CREBBP | 27 | 1.47 | 6.48E-03 | ||
| 38 | house | 42 | cellular amino acid metabolic process | 1.64E-17 | ATF4/SLC7A5/ASS1 | 26 | 1.49 | 6.37E-03 | ||
| 43 | house | 39 | organic acid catabolic process | 1.32E-12 | MUT/HMGCL/BCKDHB | 29 | 1.79 | 3.42E-05 | ||
| 45 | house | 39 | regulation of circadian rhythm | 1.58E-08 | PER2/PER3/PER1 | 29 | 1.79 | 3.42E-05 | ||
| 48 | house | 37 | ER to Golgi vesicle-mediated transport | 1.69E-07 | CREB3L2/USO1/SEC31A | 23 | 1.49 | 9.39E-03 | ||
| 67 | house | 31 | fatty acid oxidation | 5.18E-17 | ACADM/HSD17B4/HADHA | 17 | 1.32 | 9.61E-02 | ||
| 79 | house | 28 | pentose biosynthetic process | 4.50E-12 | G6PD/TALDO1/TKT | 18 | 1.54 | 1.31E-02 | ||
| 92 | house | 24 | synapsis | 6.30E-10 | DMC1/STAG3/RNF212 | 9 | 0.90 | 4.23E-01 | ||
| 97 | house | 24 | 'de novo’ posttranslational protein folding | 5.58E-11 | TUBB3/TUBA1A/TUBB2B | 10 | 1.00 | 5.77E-01 | ||
| 105 | house | 22 | ribonucleoprotein complex biogenesis | 3.16E-10 | NOLC1/TFB2M/WDR12 | 10 | 1.09 | 4.38E-01 | ||
| 213 | house | 12 | anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process | 3.13E-07 | MAD2L2/PSMC3/UBE2S | 8 | 1.60 | 7.24E-02 | ||
| 19 | immune | 58 | platelet activation | 9.22E-11 | ITGB3/CLU/F2R | 15 | 0.62 | 9.05E-03 | ||
| 24 | immune | 55 | immune response (TNFalpha)* | 1.85E-17 | TNF/IL1B/NFKB1 | 29 | 1.27 | 6.35E-02 | ||
| 27 | immune | 54 | immune system process (Osteoclast differentiation)* | 2.36E-14 | ITGB2/CD4/FCGR3B | 17 | 0.76 | 8.20E-02 | ||
| 28 | immune | 54 | platelet activation | 3.46E-09 | ILK/RAP1A/CFL1 | 37 | 1.64 | 5.83E-05 | ||
| 62 | immune | 32 | defense response to virus (Interferon alpha/beta signaling)* | 5.24E-16 | PML/EIF2AK2/BST2 | 10 | 0.75 | 1.55E-01 | ||
| 81 | immune | 27 | antigen processing and presentation of peptide antigen via MHC class I | 1.95E-14 | HLA-B/TAP1/PSMB9 | 9 | 0.80 | 2.50E-01 | ||
| 151 | immune | 16 | positive regulation of alpha-beta T cell proliferation | 2.95E-07 | IL12B/IL23A/EBI3 | 10 | 1.50 | 7.61E-02 | ||
| 160 | immune | 16 | chemokine-mediated signaling pathway | 7.80E-08 | CCR5/CCR6/CXCR6 | 2 | 0.30 | 1.32E-02 | ||
| 30 | other | 49 | regulation of transcription, DNA-templated | 9.71E-30 | ZNF267/ZNF420/ZNF92 | 35 | 1.71 | 2.29E-05 | ||
| 73 | other | 29 | cellular lipid metabolic process | 3.70E-09 | ALOX15B/FA2H/CRAT | 7 | 0.58 | 3.91E-02 | ||
| 269 | other | 10 | negative regulation of MAP kinase activity | 1.22E-12 | SPRY2/DUSP6/SPRED1 | 2 | 0.48 | 1.42E-01 | ||
| 287 | other | 9 | JAK-STAT cascade involved in growth hormone signaling pathway | 2.12E-07 | STAT3/STAT5A/STAT5B | 4 | 1.07 | 5.59E-01 | ||
| 349 | other | 6 | regulation of transposition | 5.01E-10 | APOBEC3G/APOBEC3C/APOBEC3B | 3 | 1.20 | 4.90E-01 | ||
Note: * denotes enriched pathways.
Figure 3Co-expression modules regulated by the Sp1 motif. A sub-network for development and immune response modules regulated by the Sp1 motif is shown. The size of a sphere is proportional to the number of genes within the module. The number shown within the module represents module # shown in Table 2.
Figure 4Gene expression and epigenetic regulation of Sp1 motif regulated modules. (a) The median gene expression level for genes within the Sp1-regulated modules in four human cell lines. The module numbers shown in X-axis are related to development and house-keeping categories described in Table 2. FPKM values from RNA-Seq experiments conducted by the ENCODE project is used as Y-axis. (b) The median H3K4me3 level in the promoters for genes within the Sp1-regulated modules in three human cell lines used in the ENCODE project. (c) The average promoter DNA methylation level for the genes within the Sp1-regulated modules in four human cell lines used in the ENCODE project.
Gene modules regulated by YY1, RFX2, and IRF1 motifs.
| Motif | Module No. | # of genes in the Module | Enriched GO/Pathway | GO/Pathway Enrichment pValue | Selected Genes with the enriched GO term |
|---|---|---|---|---|---|
| YY1 | 1 | 47 | cellular respiration | 1.97E-28 | SDHB/NDUFS4/NDUFS3 |
| YY1 | 4 | 31 | mitotic cell cycle | 5.62E-14 | RRM1/NDC80/RACGAP1 |
| YY1 | 7 | 27 | RNA processing | 2.41E-10 | RBM8A/RBM4/CNOT3 |
| YY1 | 10 | 25 | translational elongation | 3.34E-27 | RPSA/RPS3/RPL13A |
| YY1 | 12 | 22 | fatty acid beta-oxidation | 1.13E-06 | HADHA/ACADVL/HADHB |
| YY1 | 17 | 17 | ribosome biogenesis | 3.81E-06 | NOLC1/NIP7/CIRH1A |
| YY1 | 18 | 17 | histone modification | 2.60E-11 | EP300/CREBBP/CTCF |
| YY1 | 37 | 11 | RNA metabolic process | 5.15E-06 | PER1/POLR2A/PHF8 |
| YY1 | 42 | 10 | RNA splicing | 6.86E-11 | TARDBP/SRSF1/DDX39 |
| YY1 | 43 | 10 | type I interferon signaling pathway | 8.29E-06 | IRF1/ADAR/XAF1 |
| YY1 | 46 | 9 | regulation of mRNA processing | 4.14E-06 | CWC22/IWS1/CCDC55 |
| RFX2 | 1 | 73 | cilium morphogenesis | 9.10E-10 | ZMYND10/FOXJ1/AK7 |
| RFX2 | 2 | 48 | cilium assembly | 4.00E-19 | AHI1/CBY1/BBS1 |
| RFX2 | 4 | 20 | protein folding | 1.03E-11 | HSP90AA1/HSP90B1/HSPA1L |
| RFX2 | 5 | 14 | microtubule-based movement | 1.32E-06 | KIF14/KIF23/KIF18A |
| RFX2 | 10 | 12 | respiratory electron transport chain | 4.77E-09 | NDUFS3/CYC1/NDUFA5 |
| RFX2 | 21 | 8 | synaptic transmission | 5.03E-08 | CAMK2A/KCNIP2/SLC17A7 |
| RFX2 | 33 | 6 | regulation of striated muscle cell differentiation | 1.13E-06 | AKAP6/SMYD1/KBTBD10 |
| RFX2 | 42 | 5 | mitotic cell cycle | 5.34E-07 | PRKDC/MCM7/CENPH |
| IRF1 | 1 | 79 | Interferon alpha/beta signaling | 2.92E-30 | STAT1/MX1/ADAR |
| IRF1 | 2 | 60 | antigen processing and presentation of peptide antigen via MHC class I | 3.98E-23 | HLA-B/HLA-A/HLA-C |
| IRF1 | 3 | 35 | Interferon gamma signaling | 9.26E-07 | JAK2/CXCL10/IL12RB1 |
| IRF1 | 4 | 34 | response to virus | 3.44E-09 | CCL5/IFNB1/IL12A |
| IRF1 | 5 | 33 | synaptic transmission | 1.00E-06 | HTR2C/SNAP25/GABRG2 |
| IRF1 | 6 | 33 | hair follicle development | 8.11E-06 | NGFR/TFAP2C/SOSTDC1 |
| IRF1 | 7 | 31 | leukocyte activation | 3.80E-10 | TLR1/ICOS/CD247 |
| IRF1 | 12 | 12 | IFN alpha signaling | 3.12E-27 | IFNA17/IFNA5/IFNW1 |
| IRF1 | 13 | 10 | NOD-like receptor signaling pathway | 6.88E-06 | TLR2/NOD2/CASP1 |
| IRF1 | 18 | 7 | regulation of transposition | 4.35E-13 | APOBEC3G/APOBEC3F/APOBEC3C |
| IRF1 | 20 | 6 | neuronal action potential | 3.00E-06 | PLP1/ASPA/SCN7A |
Figure 5A gene regulatory system with different layers of regulations. The gene regulatory system consists of three layers: gene co-expression network, transcription factors network, and epigenetic regulation. Gene co-expression network capture the output of the regulatory system, i.e. the expression patterns, which are regulated by both transcription factors network and epigenetic regulation.